Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis.

J Clin Invest. 1996 Feb 1;97(3):789-98. Unique Identifier : AIDSLINE MED/96189959
Wyss-Coray T; Masliah E; Toggas SM; Rockenstein EM; Brooker MJ; Lee HS; Mucke L; Gladstone Molecular Neurobiology Program, University of; California, San Francisco 94141-9100, USA.


Abstract: HIV-1 associated central nervous system (CNS) disease involves neuronal damage and prominent reactive astrocytosis, the latter characterized by strong upregulation of the glial fibrillary acidic protein (GFAP) in astrocytes. Similar alterations are found in transgenic mice expressing the HIV-1 envelope protein gp120 in the CNS. Because alterations of astrocyte functions could contribute to neuronal impairment, we compared brains of gp120 transgenic mice and gp120-transfected C6 astrocytoma cells with controls and found that gp120 induced a prominent elevation of steady state GFAP mRNA levels, primarily due to transcript stabilization. Increased levels of GFAP mRNA were also found in nontransfected C6 cells exposed to recombinant gp120. Exposure of C6 cells or primary mouse astrocytes to soluble gp120 led to activation of PKC as indicated by redistribution and increase in PKC immunoreactivity at the single cell level. gp120 effects were diminished by inhibitors of protein kinase C (PKC) but not inhibitors of protein kinase A. PKC activity was upmodulated in gp120-transfected C6 cells and in the CNS of gp120 transgenic mice. Further, brain tissue from patients with HIV-1 encephalitis and from gp120 transgenic mice showed increased PKC immunoreactivity. Taken together, these results indicate that gp120-induced increases in PKC activity may contribute to the gliosis seen in gp120 transgenic mice as well as in HIV-1-infected humans and raise the question of whether dysregulation of signal transduction pathways represents a general mechanism of HIV-associated pathogenesis.
Keywords: Animal Astrocytes/*PATHOLOGY AIDS Dementia Complex/*ETIOLOGY Enzyme Inhibitors/PHARMACOLOGY Gene Expression Regulation Glial Fibrillary Acidic Protein/BIOSYNTHESIS/GENETICS/ISOLATION & PURIF Human HIV Envelope Protein gp120/GENETICS/*TOXICITY HIV-1/*PATHOGENICITY Immunohistochemistry Mice Mice, Mutant Strains Protein Kinase C/ANTAGONISTS & INHIB/METABOLISM Rats RNA, Messenger/METABOLISM *Signal Transduction Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDanimalastrocytes/KWDpathologyaidsdementiacomplex/KWDetiologyenzymeinhibitors/pharmacologygeneexpressionregulationglialfibrillaryacidicprotein/biosynthesis/genetics/isolation&purifhumanhivenvelopeproteingp120/genetics/KWDtoxicityhiv-1/KWDpathogenicityimmunohistochemistrymicemice,mutantstrainsproteinkinasec/antagonists&inhib/metabolismratsrna,messenger/metabolismKWDsignaltransductionsupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
960830
M9681190

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .